Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Biotechnology

Healthcare
$19.17 -1.71%

-$0.22 today

Market cap
$676.80M
Beta
1.08
P/E (TTM)
-36.5
EPS (TTM)
-$0.24
52W Low $7.59High $14.24

Volume 0.00M

Average 0.00M

FRX.TO EBITDA Margin

EBITDA as a percentage of revenue.

Fennec Pharmaceuticals Inc.TSX: FRX.TO

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 1.6%

EBITDA Margin was 1.6% in Q1 FY2026, up 7.8 pp from a year earlier. On a trailing-twelve-month basis it was -10.5%, up 23.0 pp year over year. Over 3 fiscal years it widened by 1464.5 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 20.6% for the fiscal year ending Dec 2026, up from -16.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
1.6%+23.4 pp QoQ
Last fiscal yearDec 2025
-16.7%-26.8 pp YoY
LTMMar 2026
-10.5%+23.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+7.8 pp+32.4 pp+24.6 pp
1 year-26.8 pp+37.3 pp+64.1 pp
3 years+1464.5 pp+62.1 pp-1402.4 pp
5 years+70.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-16.7%
Year-over-year change
-26.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How FRX.TO compares with its peers on the latest reported figures

  • FRX.TO's LTM Mar 2026 EBITDA Margin of -10.5% is the 3rd highest of the 6 companies compared; the peer median is -14.9%.
  • Its year-over-year change of +23.0 pp is the 3rd highest of 6, against a peer median of +19.6 pp.
  • Over three fiscal years its change of +1464.5 pp compares with a peer median of +135.8 pp.
FRX.TO Competitors Peer median
EBITDA Margin for FRX.TO and competitors
Company Period LTM level YoY 3-year change
DR.TOMedical Facilities CorporationLTM Mar 202624.7% -1.0 pp+10.9 pp
TSND.TOTerrAscend Corp.LTM Mar 202623.1% +19.6 pp+126.3 pp
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026-10.5% +23.0 pp+1464.5 pp
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026-14.9% -18.5 pp—
WEED.TOCanopy Growth CorporationLTM Mar 2026-20.4% +157.8 pp+798.1 pp
PRN.TOProfound Medical Corp.LTM Mar 2026-194.3% +121.3 pp+145.4 pp
EPRX.TOEupraxia Pharmaceuticals Inc.FY2025— ——
HBP.TOHelix BioPharma Corp.FY2025— ——
Peer median (excluding FRX.TO) -14.9%+19.6 pp+135.8 pp

Competitors are the stored peer set for FRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.54M21.25M47.54M44.64M
Cost of Revenue086K1.26M3.18M3.76M
Gross Profit01.45M19.99M44.35M40.88M
Gross Margin—94.4%94.1%93.3%91.6%
Research & Development4.98M3.53M56K307K254.38K
Selling, General & Admin12.24M20.51M32.71M41.48M46.91M
Operating Expenses17.22M24.04M32.76M41.79M47.22M
Depreciation & Amortization17.22M149K287K800K103K
EBITDA(17.19M)(22.74M)(12.65M)4.8M(7.45M)
EBITDA Margin—-1481.2%-59.5%10.1%-16.7%
Operating Income(17.22M)(22.59M)(12.77M)2.57M(6.35M)
Operating Margin—-1471.6%-60.1%5.4%-14.2%
Interest Income54K195K441K1.68M800.78K
Interest Expense126K978K3.39M4.07M2.18M
Other Income / Expenses(123K)(1.13M)(3.27M)(2.64M)(3.29M)
Income Before Tax(17.35M)(23.71M)(16.05M)(71K)(9.64M)
Pre-Tax Margin—-1544.9%-75.5%-0.1%-21.6%
Income Tax Expense110K147K0365K106K
Net Income(17.46M)(23.86M)(16.05M)(436K)(9.74M)
Net Margin—-1554.5%-75.5%-0.9%-21.8%
EPS (Basic)(0.67)(0.91)(0.60)(0.02)(0.34)
EPS (Diluted)(0.67)(0.91)(0.60)(0.02)(0.34)
Weighted Avg Shares25.89M26.28M26.57M21.8M28.58M
Weighted Avg Shares (Diluted)26.01M26.28M26.57M27.3M28.58M

Fennec Pharmaceuticals Inc.

TSX:FRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$19.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.